Armenia-based neutrality
An Armenia-based legal and operational platform lowers geopolitical friction and improves sponsor comfort.
Armenia-based rare-disease CRO
Rare-disease clinical execution for under-served EAEU and CIS populations
Boutique CRO connecting global sponsors, CIS innovators, and regional access alliances through the FMF Registry — the world's largest single-source autoinflammatory cohort of 14,500+ patients.
- Armenia-based legal and operational platform
- Rare-disease and registry-first focus
- Regional access without Russia-first public positioning
Anchor proof
14,500+
14,500+ patients in the world's largest single-source FMF cohort.
Explore the FMF Registry →FMF Registry · Anchor asset
14,500+
patients · pediatric-to-adult · genotype + phenotype linkage
The Armenian FMF Registry is positioned as MRG's main proof asset for feasibility, natural-history analysis, registry-based planning, and sponsor dialogue.
Request Registry Feasibility BriefWhy this matters now
When traditional routes slow down, the value of more flexible regional platforms rises.
For rare-disease programs, speed of patient identification, access to investigator-ready sites, and disease-level feasibility increasingly matter more than the scale of a generic CRO footprint.
Market friction
- Difficult patient finding
- Long path to site activation
- Limited disease-specific visibility
- Low flexibility from large providers
How MRG responds
- Focused feasibility
- Registry-first planning logic
- Clinician-aware execution
- Compact and accountable operating model
Why Armenia · Why MRG
Boutique execution, sponsor-grade discipline.
Rare-disease specialization
MRG is not positioned as a generalist CRO; it is focused on rare and complex disease programs where disease understanding and patient mapping matter.
Regional access
The team combines an Armenian operating base with EAEU/CIS knowledge and Russian-speaking operational depth.
Registry-first proof
The FMF Registry is treated as a real evidence asset around which feasibility, observational design, and sponsor discussions can be built.
Who we help
Three commercial trajectories. One operating platform.
US · EU · JP
Global Sponsors
Rare-disease execution with sponsor-grade QMS / GCP delivery.
Learn more →→ GCC · MENA · SEA
CIS Innovators
Market-access preparation for regulatory bridging beyond CIS.
Learn more →EAEU · Central Asia
Regional Alliances
Neutral coordination for cross-border access programs.
Learn more →Focus areas
Six rare-disease clusters.
FMF & Autoinflammatory Diseases
FMF, CAPS, TRAPS, HIDS, Behçet's, adult-onset Still's.
Orphan Hematology
Hemophilia, HAE, PNH and other small-population hematology pathways.
Rare Oncology & Hemato-Oncology
Narrow indications where site readiness and referral logic are critical.
Rare Neurology & Neuromuscular
SMA, myasthenia gravis, Duchenne and complex neuromuscular routes.
Pediatric Rare Diseases
Age-appropriate operational design across every trial layer.
Rare Metabolic & Lysosomal Storage Disorders
Registry logic and natural-history evidence for Gaucher, Fabry and related diseases.
Capabilities snapshot
What MRG can take on.
- Feasibility & Site Selection
- Clinical Trial Execution
- Regulatory Affairs & Registration
- Medical & Scientific Writing
- Data Management & Biostatistics
- Real-World Evidence & Registry Design
- Pharmacovigilance
Productized offers
Start with a clear entry product.
ICP-A
Global Sponsors
ICP-A · JP
Japan-Ready Execution
ICP-B
CIS Innovator Access
ICP-C
Regional Access Alliances
Bridge
EAEU Registration Bridge
RWE
Post-Market Evidence
Trust & Quality
Sponsor-grade governance and transparency.
GCP & QMS
ICH-GCP aligned quality system and sponsor-visible operating rigor.
Inspections & Certifications
Documented inspection language, SOP framework, and controlled evidence handling.
Data Privacy & Governance
Role-based access, de-identification discipline, and clear stewardship logic.
Resources
Materials that help a sponsor decide.
FMF Feasibility Dossier
24-page briefing asset for sponsor feasibility conversations.
Registry Readiness Brief
Registry design and evidence-readiness perspective for planning discussions.
Events & News
BIO, DIA and rare-disease conference participation and updates.
Main CTA
Start with a concrete entry product.
Use the contact flows to request the FMF dossier, discuss feasibility, open a registry collaboration, explore an EAEU bridge, or begin partner onboarding.